Sinopharm (kompaniya) sahifasining manbasini koʻrish

 {{Infobox company|name=China National Pharmaceutical Group|trade_name=Sinopharm|logo=Sinopharm logo.svg|logo_size=|logo_alt=|logo_caption=|logo_padding=|image=|image_size=|image_alt=|image_caption=|type=[[Davlatga tegishli korxona]]|industry=|founded=1998-yil 26-noyabr|founder=|former_name=|hq_location=20 Zhichun Road, Haidian okrugi|hq_location_city=Pekin|hq_location_country=Xitoy|area_served=Xitoy, butun dunyoga eksport qilinadi|num_locations=|num_locations_year=|num_employees=|num_employees_year=|key_people=Liu Jingzhen (Rais & [[Xitoy Kommunistik partiyasi qoʻmitasi kotibi]])<ref>{{veb manbasi|url=http://www.sinopharm.com/s/1223-3764-36260.html|title=中国医药集团有限公司主要领导调整|publisher=Sinopharm|language=zh|qaralgan sana=2022-09-08|arxivsana=2022-09-08|arxivurl=https://web.archive.org/web/20220908065805/http://www.sinopharm.com/s/1223-3764-36260.html}}</ref><ref>{{veb manbasi|url=https://www.bloomberg.com/profile/person/21371288|title=Liu Jingzhen|publisher=Bloomberg|language=en}}</ref>|brands=|services=|revenue={{increase}} {{CNY|247.110&nbsp;[[1,000,000,000|mlrd]]}}|revenue_year=2014|operating_income={{increase}} {{CNY|8.758&nbsp;mlrd}}|income_year=2014|net_income={{increase}} {{CNY|2.705&nbsp;mlrd}}|net_income_year=2014|assets={{increase}} {{CNY|199.192&nbsp;mlrd}}|assets_year=2014|equity={{increase}} {{CNY|31.944&nbsp;mlrd}}|equity_year=2014|owner=[[Davlat Kengashining Davlat aktivlarini nazorat qilish va boshqarish komissiyasi|Chinese&nbsp;central&nbsp;government]]&nbsp;(100%)|parent=[[Davlat Kengashining Davlat aktivlarini nazorat qilish va boshqarish komissiyasi| Davlat konsulligining SASAC]]|subsid={{ubl|Sinopharm&nbsp;Industrial&nbsp;Investment&nbsp;(51%)|→ [[Sinopharm Group]] (56.79%)|[[China Traditional Chinese Medicine|Trad. Chinese Medicine]] (37.59%)|[[Shanghai Shyndec Pharmaceutical|Shyndec Pharma.]] (41.62%)|China National Biotec Group (95%)|→ [[Beijing Tiantan Biological Products|Tiantan Biological]] (53.30%)}}|rating=|footnotes=konsolidatsiyalangan asosda; ozchilikning ulushlari bundan mustasno, kapital va foyda; Xitoyning buxgalteriya hisobi standartlarida<ref>{{veb manbasi|url=http://www.shclearing.com/xxpl/fxpl/scp/201601/t20160119_126134.html|title=中国医药集团总公司2016年度第一期超短期融资券发行披露材料|trans-title=Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm|date=19 January 2016|access-date=22 November 2016|work=Sinopharm|publisher=Shanghai Clearing House|language=zh|arxivsana=2021-04-15|arxivurl=https://web.archive.org/web/20210415104106/https://www.shclearing.com/xxpl/fxpl/scp/201601/t20160119_126134.html}}</ref>|module={{Chinese
| child=yes
|s=中国医药集团总公司
|t=中國醫藥集團總公司
|p=Zhōngguó yīyào jítuán zǒng gōngsī
|order=st
| altname=short Chinese name
|s2=国药集团
|t2=國藥集團
|p2=Guóyào jítuán
}}}}'''Xitoy milliy farmatsevtika guruhi korporatsiyasi''' ('''CNPGC'''), odatda '''Sinopharm''' deb ataladi, Xitoy davlat korxonasi. Korporatsiya Sinopharm Group (SEHK: 51-49 qoʻshma korxonasi orqali Sinopharm Industrial Investment, Fosun Pharmaceutical bilan), China Traditional Chinese Medicine,<ref>{{Veb manbasi|url=http://www.hkexnews.hk/listedco/listconews/SEHK/2016/0428/LTN201604282264.pdf|sarlavha=2015 Annual Report|sana=28 April 2016|kirish sanasi=22 November 2016|ish=China Traditional Chinese Medicine|nashriyot=Hong Kong Stock Exchange}}</ref> Shanghai Shyndec Pharmaceutical va Beijing Tiantan Biological Products kompaniyaning aksiyalariga egalik qiladi. Xitoy Milliy farmasevtika guruhi Davlat Kengashining Davlat aktivlarini nazorat qilish va boshqarish komissiyasi tomonidan nazorat qilinadi.<ref>{{Veb manbasi|sarlavha=央企名录 (List of Central SOEs)|url=http://www.sasac.gov.cn/n86114/n86137/index.html|ish=Official website of SASAC|kirish sanasi=3 March 2016|til=zh}}</ref> Sinopharm 2021-yilgi Fortune Global 500 roʻyxatida 109-oʻrinni egalladi.<ref>{{Veb manbasi|url=https://fortune.com/global500/search/?name=Sinopharm|sarlavha=Global 500}}</ref>

== Tarix ==
Sinopharm '''Xitoy milliy farmatsevtika guruhi korporatsiyasi''' (Xitoycha, 中国医药集团总公司, 1998-yil 26-noyabrda China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (xitoycha, 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (xitoycha, 中国医药对外贸易公司 ) va China National Medical Device (xitoycha, 中国医疗器械工业公司)) sifatida tashkil etilgan va 2009-yilda u China National Biotec Group (xitoycha, 中国生物技术集团公司) bilan birlashtirilgan.

Uning sho‘ba korxonasi Wuhan Biologik mahsulotlar instituti 2017-yil noyabr oyida 400 520 ta samarasiz DPT vaksinalarini sotgani uchun jarimaga tortildi <ref>{{Yangiliklar manbasi |date=23 July 2018 |title=Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal |publisher=South China Morning Post |url=https://www.scmp.com/news/china/policies-politics/article/2156431/chinese-premier-li-keqiang-promises-clean-vaccine |access-date=29 November 2018}}</ref>

== Covid-19 vaksinalari ==
'''Sinopharm BIBP COVID-19 vaksinasi''', shuningdek, '''BBIBP-CorV''',<ref name=":0">{{Cite journal|display-authors=6|title=Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial|journal=The Lancet. Infectious Diseases|volume=21|issue=1|pages=39–51|date=January 2021|pmid=33069281|pmc=7561304|doi=10.1016/s1473-3099(20)30831-8}}</ref> '''Sinopharm COVID-19 vaksinasi''',<ref name="who-faq">{{Yangiliklar manbasi |date=10 May 2021 |title=The Sinopharm COVID-19 vaccine: What you need to know |publisher=World Health Organization |url=https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know |access-date=5 July 2021}}</ref> yoki '''BIBP vaksinasi'''<ref name="who-faq" /><ref>{{Yangiliklar manbasi |date=5 June 2021 |title=Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it? |work=South China Morning Post |url=https://www.scmp.com/week-asia/health-environment/article/3136137/coronavirus-vietnam-approves-sinopharms-vaccine-will |access-date=5 July 2021}}</ref><ref>{{Yangiliklar manbasi |date=16 June 2021 |title=What we now know about the efficacy of China's Covid-19 vaccines |work=Quartz |url=https://qz.com/2018838/what-we-know-about-efficacy-of-sinopharm-sinovac-vaccines/ |access-date=5 July 2021}}</ref> sifatida ham tanilgan, bu ikki [[Inaktivatsiyalangan vaksina|faolsizlantirilgan]] COVID-19 virusidan biridir. Sinopharm tomonidan ishlab chiqilgan vaksinalar . U [[Argentina]], [[Bahrayn]], [[Misr]], [[Marokash]], [[Pokiston]], [[Peru]] va [[Birlashgan Arab Amirliklari|Birlashgan Arab Amirliklarida]] (BAA) 60 000 dan ortiq ishtirokchi bilan III bosqich sinovlarini yakunladi.<ref name=":52">{{Yangiliklar manbasi |last=Reuters Staff |date=2020-11-19 |title=China Sinopharm's coronavirus vaccine taken by about a million people in emergency use |work=Reuters |url=https://www.reuters.com/article/us-health-coronavirus-vaccine-sinopharm-idUSKBN27Z0PY |access-date=2020-12-09}}</ref> BBIBP-CorV shunga oʻxshash texnologiyani [[CoronaVac]] va [[Kovaksin|BBV152]], COVID-19 uchun boshqa faollashtirilgan virus vaksinalarida ham foydalanadi. <ref name=":27">{{Yangiliklar manbasi |last=Corum |first=Jonathan |last2=Zimmer |first2=Carl |date=2021-04-26 |title=How the Sinopharm Vaccine Works |work=The New York Times |url=https://www.nytimes.com/interactive/2020/health/sinopharm-covid-19-vaccine.html |access-date=2021-04-29 |issn=0362-4331}}</ref>

[[Birlashgan Arab Amirliklari]] va [[Bahrayn|Bahrayndagi]] III bosqich sinovlarining [[Amerika Tibbiyot Assotsiatsiyasi jurnali|JAMA]]<nowiki/>da eʼlon qilingan ekspertlar tomonidan koʻrib chiqilgan natijalar BBIBP-CorV ning simptomatik holatlarga qarshi 78,1% va ogʻir holatlarga qarshi 100% samarali ekanligini koʻrsatdi (emlangan guruhda 21 holat va platsebo guruhida 95 holat).<ref name="jama.2021.8565">{{Cite journal|last=Kaabi|first1=Nawal Al|last2=Zhang|first2=Yuntao|last3=Xia|first3=Shengli|last4=Yang|first4=Yunkai|last5=Qahtani|first5=Manaf M. Al|last6=Abdulrazzaq|first6=Najiba|last7=Nusair|first7=Majed Al|last8=Hassany|first8=Mohamed|last9=Jawad|first9=Jaleela S.|display-authors=3|date=May 26, 2021|title=Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial|journal=JAMA|language=en|doi=10.1001/jama.2021.8565|volume=326|issue=1|pages=35–45|pmid=34037666|pmc=8156175}}</ref> 2020-yil dekabr oyida BAA avvalroq 86% samaradorlikni ko‘rsatuvchi oraliq natijalarni e’lon qildi.<ref>{{Veb manbasi|sarlavha=UAE: Ministry of Health announces 86 per cent vaccine efficacy|url=https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571|kirish sanasi=2020-12-13|ish=gulfnews.com|til=en}}</ref> [[Pfizer/BioNTech COVID-19 vaksinasi|Pfizer-BioNTech COVID-19 vaksinasi]] va [[Moderna COVID-19 vaksinasi|mRNA-1273]] kabi mRNK vaksinalari 90% dan yuqori samaradorlikni koʻrsatgan boʻlsa-da, ular baʼzi davlatlar uchun tarqatishda qiyinchiliklar tugʻdiradi, chunki ular chuqur muzlatish uskunalari va yuk mashinalarini talab qiladi. BIBP-CorV esa normal sovitilgan haroratda tashilishi va saqlanishi mumkin.<ref name=":62">{{Yangiliklar manbasi |date=2020-12-09 |title=China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says |language=en |work=Bloomberg.com |url=https://www.bloomberg.com/news/articles/2020-12-09/uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19 |access-date=2020-12-09}}</ref>

BBIBP-CorV Osiyo,<ref name=":122">{{Yangiliklar manbasi |date=2020-12-31 |title=China gives its first COVID-19 vaccine approval to Sinopharm |work=Reuters |url=https://www.reuters.com/article/us-health-coronavirus-vaccine-china-idUSKBN29505P |url-status=live |access-date=2020-12-31}}</ref><ref name=":26">{{Veb manbasi|muallif=Turak|ism=Natasha|sana=2021-01-18|sarlavha=The UAE is on track to have half its population vaccinated by the end of March|url=https://www.cnbc.com/2021/01/18/uae-on-track-to-vaccinate-half-its-population-by-end-of-march-.html|kirish sanasi=2021-01-21|ish=CNBC}}</ref><ref name=":72">{{Veb manbasi|muallif=Dawn.com|sana=2021-02-02|sarlavha=PM Imran kicks off Pakistan's Covid-19 vaccination drive|url=https://www.dawn.com/news/1605089|kirish sanasi=2021-02-03|ish=DAWN.COM|til=en}}</ref> Afrika,<ref name=":92">{{Yangiliklar manbasi |last=Reuters Staff |date=2021-01-24 |title=Sisi says Egypt to begin COVID-19 vaccinations on Sunday |work=[[Reuters]] |url=https://www.reuters.com/article/us-health-coronavirus-egypt-vaccinations-idUSKBN29T05N |access-date=2021-01-24}}</ref><ref name=":152">{{Veb manbasi|muallif=Dumpis|ism=Toms|sana=2021-01-27|sarlavha=Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine|url=https://www.moroccoworldnews.com/2021/01/333436/morocco-receives-half-a-million-doses-of-chinese-sinopharm-vaccine/|kirish sanasi=2021-01-28|ish=Morocco World News}}</ref><ref name=":112">{{Veb manbasi|sana=2021-02-18|sarlavha=Zimbabwe starts administering China's Sinopharm vaccines|url=https://www.thestar.com/news/world/africa/2021/02/18/zimbabwe-starts-administering-chinas-sinopharm-vaccines.html|kirish sanasi=2021-02-20|ish=thestar.com|til=en}}</ref> Janubiy Amerika,<ref name=":252">{{Veb manbasi|sarlavha=Argentina autoriza la vacuna china Sinopharm para mayores de 60 años|url=https://www.elcomercio.com/actualidad/argentina-vacuna-china-sinopharm-adultos.html|kirish sanasi=2021-03-26|ish=El Comercio}}</ref><ref name=":162">{{Yangiliklar manbasi |last=Aquino |first=Marco |date=2021-02-10 |title='The best shield': Peru launches inoculation drive with Sinopharm vaccine |language=en |work=Reuters |url=https://www.reuters.com/article/us-health-coronavirus-peru-vaccine-idUSKBN2AA03U |access-date=2021-02-10}}</ref><ref name=":232">{{Veb manbasi|sarlavha=Bolivia begins inoculation with Sinopharm jabs {{!}} The Star|url=https://www.thestar.com.my/aseanplus/aseanplus-news/2021/02/26/bolivia-begins-inoculation-with-sinopharm-jabs|kirish sanasi=2021-02-28|ish=www.thestar.com.my}}</ref> va Yevropaning ayrim mamlakatlarida emlash kampaniyalarida qoʻllanilmoqda.<ref name=":172">{{Veb manbasi|sarlavha=Serbia Becomes First European Nation To Use China's Sinopharm Vaccine|url=https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html|kirish sanasi=2021-01-21|ish=RadioFreeEurope/RadioLiberty}}</ref><ref name=":212">{{Veb manbasi|sana=2021-02-24|sarlavha=Hungary first EU nation to use China's Sinopharm vaccine against COVID|url=https://www.euronews.com/2021/02/24/hungary-becomes-first-eu-nation-to-use-china-s-sinopharm-vaccine-against-covid-19|kirish sanasi=2021-02-26|ish=euronews|til=en}}</ref><ref name=":242">{{Veb manbasi|sana=2021-03-15|sarlavha=Belarus begins COVID-19 vaccinations with Chinese shots|url=https://eng.belta.by/society/view/belarus-begins-covid-19-vaccinations-with-chinese-shots-138222-2021/|kirish sanasi=2021-03-16|ish=eng.belta.by|til=en-EN}}</ref> Sinopharm 2021-yilda bir milliard dozada BBIBP-CorV ishlab chiqarishni kutmoqda<ref name=":222">{{Veb manbasi|sana=2021-02-05|sarlavha=Which companies will likely produce the most COVID-19 vaccine in 2021?|url=https://www.pharmaceuticalprocessingworld.com/which-companies-will-likely-produce-the-most-covid-19-vaccine-in-2021/|kirish sanasi=2021-02-28|ish=Pharmaceutical Processing World|til=en-US}}</ref> 2021-yil 7-mayda [[Jahon sogʻliqni saqlash tashkiloti|Jahon sog‘liqni saqlash tashkiloti]] vaksinani favqulodda foydalanish uchun tasdiqladi<ref name="WHOEUA">{{Yangiliklar manbasi |last=Taylor |first=Adam |date=7 May 2021 |title=WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine |work=[[The Washington Post]] |url=https://www.washingtonpost.com/world/2021/05/07/who-sinopharm-emergency-use/ |access-date=7 May 2021}}</ref> va Sinopharm keyinchalik COVAX dan 170 million dozaga sotib olish shartnomalarini imzoladi.<ref name=":282">{{Veb manbasi|sana=2021-07-12|sarlavha=Chinese drugmakers agree to supply more than half a billion vaccines to COVAX|url=https://www.reuters.com/world/gavi-signs-covid-19-vaccine-supply-deals-with-sinovac-sinopharm-covax-2021-07-12/|kirish sanasi=2021-07-13|ish=Reuters}}</ref>

Xuddi shunday nomlangan Sinopharm WIBP COVID-19 vaksinasi ham inaktivatsiyalangan virusli vaksinadir.

== Manbalar ==
<references group="" responsive="0"></references>